CYTOKINETICS director granted 191 CYTK shares

Harrington Robert Arthur reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Harrington Robert Arthur reported acquisition or exercise transactions in this Form 4 filing.

CYTOKINETICS INC director Robert Arthur Harrington received a grant of 191 shares of Common Stock as equity compensation. The shares were granted under a Director Equity in Lieu of Cash Retainer Program and are fully vested, meaning he owns them outright. Following this award, he directly holds 18,930 shares of CYTOKINETICS INC common stock.

Insider Trade Summary

Grant/Award: 191 shares

Grant/Award 1 txn

Insider Harrington Robert Arthur

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	191	$65.37	$12K

Holdings After Transaction: Common Stock — 18,930 shares (Direct)

Footnotes (1)

1. F1. Shares of common stock granted pursuant to Director Equity in Lieu of Cash Retainer Program. Shares are fully vested.

Key Figures

Equity grant size: 191 shares Grant valuation price: $65.37 per share Post-grant holdings: 18,930 shares

3 metrics

Equity grant size 191 shares Common Stock grant to director on 2026-04-15

Grant valuation price $65.37 per share Reported price for 191 granted shares

Post-grant holdings 18,930 shares Total common shares held directly after transaction

Key Terms

Director Equity in Lieu of Cash Retainer Program, fully vested, Grant, award, or other acquisition

3 terms

Director Equity in Lieu of Cash Retainer Program financial

"Shares of common stock granted pursuant to Director Equity in Lieu of Cash Retainer Program."

fully vested financial

"Shares are fully vested."

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CYTK director Robert Harrington report?

Director Robert Arthur Harrington reported receiving 191 shares of CYTOKINETICS INC common stock as an equity grant. The award was made under a Director Equity in Lieu of Cash Retainer Program and represents compensation rather than an open-market purchase or sale.

At what price were the CYTK shares granted to director Robert Harrington?

The 191 granted shares were valued at $65.37 per share. This price is used for reporting the fair value of the equity award and does not reflect an open-market purchase, as the shares were provided as compensation, not bought in the market.

How many CYTOKINETICS (CYTK) shares does Robert Harrington hold after this grant?

After the reported grant, Robert Arthur Harrington directly owns 18,930 shares of CYTOKINETICS INC common stock. This total includes the newly granted 191 fully vested shares received as part of the company’s director equity compensation program.

Is the CYTK equity award to Robert Harrington fully vested?

Yes, the 191-share equity award to Robert Arthur Harrington is fully vested. Being fully vested means he has complete ownership of these shares immediately, without future service or performance conditions attached to the grant.

Was Robert Harrington’s CYTK transaction a market buy or sell?

The transaction was not a market buy or sell; it was a grant classified as a “Grant, award, or other acquisition.” Harrington received 191 shares of CYTOKINETICS INC common stock as director compensation rather than trading shares on the open market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/15/2026 - 06:33 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Harrington Robert Arthur

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/15/2026		A(1)		191	A	$65.37	18,930	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares of common stock granted pursuant to Director Equity in Lieu of Cash Retainer Program. Shares are fully vested.

	/s/ John Faurescu, attorney-in-fact for Dr. Harrington	04/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)